COVAXIN shows 78% clinical and 100% efficacy against severe COVID-19
The COVAXIN developed and manufactured by Bharat Biotech, “neutralizes multiple variants of SARS-COV-2 and effectively neutralises the double mutant strain as well,” the ICMR statement.
According to the Indian Council of Medical Research on Wednesday said Covaxin has shown an overall interim clinical efficacy of 78% and a 100% efficacy against severe Covid-19 disease. The efficacy was announced on the basis of a second interim analysis after more than 87 symptomatic cases of Covid-19 were reported among the Phase 3 trials volunteers of Covaxin.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…